Introduction

The detection of subclinical atherosclerotic lesions such as asymptomatic atherosclerotic plaques helps in identifying individuals in whom an atherosclerotic process is already present. These subjects have higher risk of cardiovascular events than those without atherosclerotic deterioration of the arterial wall. During the last decade, plaque structure composition rather than the degree of stenosis has proved to be a far more important trigger of thromboembolic events. Therefore, in addition to the detection of morphological characteristics of atherosclerotic plaques, recent research has focused on investigating the physiological...
processes, particularly inflammatory activity of atherosclerotic plaques, which help in identifying unstable atherosclerotic lesions and “vulnerable” patients. Evidence that inflammatory processes are pivotal in the development of unstable atherosclerotic lesions and related to complications is growing. Inflammation destabilizes atherosclerotic plaques and promotes their rupture by enzymatic degradation of their fibrous structure. Therefore, the inflammation of atherosclerotic plaque is associated with a significant increase in cardiovascular events. Identification of unstable atherosclerotic plaques helps in identifying patients who are at a higher risk and need more intensive treatment of atherosclerosis risk factors.

There are different methods for detecting unstable atherosclerotic lesions. Invasive intravascular techniques are not acceptable for everyday clinical practice. Noninvasive identification of atherosclerotic processes has been a challenging task. High-resolution ultrasound is one of the noninvasive methods for identifying carotid atherosclerosis. However, it only provides evaluation and insight into the morphology of atherosclerotic lesions of the extracranial and some other peripheral arteries. In addition, it gives no information regarding inflammation and metabolic status of the atherosclerotic lesions. Blockmans et al. were the first to report that 18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) imaging is useful in detecting large vessel inflammation. Recent studies have demonstrated that PET imaging in combination with contrast-enhanced computed tomography (CT) or magnetic resonance imaging enables visualization of 18F-FDG uptake in carotid plaques and that 18F-FDG accumulation is associated with the inflammation of atherosclerotic plaques related to macrophage infiltration. More recently, it was shown that 18F-FDG-PET/CT enables very precise measurement of the inflammatory activity of atherosclerotic plaques in large- and medium-sized arteries.

In a previous study, we investigated the intensity of 18F-FDG uptake in the carotid and femoral arteries and compared it with the histological findings in the corresponding specimens obtained during carotid and femoral endarterectomy. We discovered a significant interrelationship between 18F-FDG uptake and the accumulation of inflammatory cells in carotid and femoral atherosclerotic lesions. 18F-FDG-PET imaging is relatively complicated, time consuming, and not completely noninvasive; therefore, investigators have been searching for other less complicated and noninvasive techniques for the identification of vessel wall inflammation. As inflammation of an individual organ system usually triggers a systemic inflammatory response, we expected that in patients with atherosclerotic inflammatory lesions of vessel wall, inflammatory markers in systemic blood, particularly those which indicate inflammation of the arterial wall (interleukins), would be increased. Therefore, the aim of the study was to investigate the relationship between the inflammation of carotid and femoral atherosclerotic plaques determined by PET/CT and levels of systemic inflammatory markers and to identify patients at high risk for cardiovascular events on the basis of the investigation of blood constituents.

### Materials and Methods

#### Study Design and Participants

The study included 37 patients, 21 with high-grade stenosis of the internal carotid artery (ICA) (≥70% luminal narrowing) and 16 with occlusion of the common femoral artery (CFA), who underwent endarterectomy of ICA or CFA, respectively. There were 24 (65%) males and 13 (35%) females. The mean age of the study population was 69.43 ± 6.2 years, and there were no statistically significant differences in the age between males and females (68.9 vs. 70.7 years, p = 0.470). Eight out of the 21 patients with stenosis of the ICA were symptomatic: three had unilateral amaurosis fugax, four suffered a transitory ischemic attack, and one suffered a hemispheric stroke. All patients with occlusion of CFA were symptomatic; four of them fulfilled the criteria for critical limb ischemia (rest pain, ankle brachial pressure <50 mmHg), and the others had limiting intermittent claudication. The diagnosis was first confirmed by Duplex ultrasonography and then by CT angiography. Both groups were compared with a sex- and age-matched control group composed of 27 healthy volunteers.

The study was conducted according to the ethical principles stated in the Declaration of Helsinki. The study protocol was approved by the National Ethical Committee, and all patients provided written consent.

#### 18F-FDG-PET Imaging

Before the operative procedure (endarterectomy), 18F-FDG-PET imaging was performed in all patients. After at least 12 h of fasting, the serum glucose level was checked using a finger stick, and a 20-gauge intravenous (iv) line was inserted to administer the radio tracer. The study patients received 370 MBq of 18F-FDG intravenously. One hour after iv 18F-FDG administration, low-dose CT imaging of the region of interest was performed (120 kV, 50 mA, and slice thickness 3 mm) from the external auditory meatus to...
Continuous variables were expressed as means ± standard deviation (SD). For comparison of the continuous variables, the Mann–Whitney U test was used, and the chi-square or Fisher's exact test was used for comparison of categorical data. Pearson's correlation coefficient method was used to assess the correlation between PET maximal TBR and levels of circulating markers. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp., USA.

Results

Thirty-seven patients and 27 healthy controls were enrolled in the study: 21 with ICA stenosis (8 symptomatic and 13 asymptomatic) and 16 with occlusion of CFA. The study included patients who successfully underwent endarterectomy; their characteristics are shown in Table 1. There were no significant differences in age between patients with carotid and femoral atherosclerosis (p=0.47) or between males and females (p=0.43).

All patients were at high risk of cardiovascular events; three of them had only one risk factor of atherosclerosis, and in the others, two or more classical risk factors were present. Arterial hypertension was most frequently present, followed by hyperlipoproteinemia, diabetes mellitus, and smoking. There were no significant differences in the presence of risk factors...
between patients with carotid and femoral atherosclerosis, with the exception of smokers or former smokers who represented 50% of patients in the CFA group and 16% of the subjects with carotid stenosis (Table 1). In the control group, five subjects had increased blood pressure and four had dyslipidemia.

Table 2 shows the levels of systemic inflammatory markers and t-PA Ag values of the investigated patient groups and controls. With an exception of IL-6, which was higher in patients with carotid stenosis, there were no significant differences in the levels of inflammatory markers between patients with ICA stenosis and patients with occluded CFA. Between controls and both patient groups, significant differences were detected in IL-6 and TNF-α levels. Both markers were significantly lower in healthy controls compared with the patients. The values of 18F-FDG-PET were also comparable between the investigated patient groups (Table 3). In subjects with ICA stenosis, maximal TBR was not significantly different compared with patients with CFA occlusion.

Table 4 presents the interrelationship between 18F-FDG-PET and levels of systemic inflammatory markers. A close relationship between the 18F-FDG uptake presented as maximal TBR and circulating inflammatory markers, such as IL6, hsCRP, and TNF-α, was proven and a borderline significant interrelationship was indicated between P-selectin levels and 18F-FDG-PET.

There were no statistically significant differences in the levels of systemic inflammatory markers determined before endarterectomy compared with the levels after endarterectomy in the ICA and CFA groups, respectively (Table 5).

**Discussion**

The structure of atherosclerotic plaques is most probably an essential element in thromboembolic complications of atherosclerosis, and inflammation may play an important role in plaque vulnerability or stability. Inflammatory processes within the arterial wall were initiated mainly in response to endogenously modified structures, particularly oxidized lipoproteins, which lead to further alteration of the vascular wall and promote disease progression. The associations between inflammation of atherosclerotic lesion and
cardiovascular events \(^{(14)}\) have led to the development of techniques that can measure the intensity of inflammation of the vessel wall. As shown in our previous study and in other studies, \(^{18}\)F-FDG-PET/CT is able to detect and quantify inflammation within carotid and femoral atherosclerotic lesions \(^{(10)}\). \(^{18}\)F-FDG uptake in the arteries shows a good correlation with different risk factors of atherosclerosis and correlates with macrophage quantities within the atherosclerotic plaques \(^{(12)}\). However, its specificity is relatively low because an increased \(^{18}\)F-FDG glucose uptake is also present in lesions \(^{(19)}\). However, its specificity is relatively low because an increased \(^{18}\)F-FDG glucose uptake is also present in other diseases with high metabolic processes as well as in malignant diseases.

Recently, various circulating markers have been evaluated as indicators of plaque inflammation. In addition, their sensitivity to reveal which patient may benefit from intensified medical treatment that stabilizes atherosclerotic plaques has been evaluated \(^{(15)}\).

Circulating markers, which are indicators of vessel wall inflammation, are of particular interest. Some cytokines such as IL-6 and IL-18 have been identified to play a role in the late stages of atherosclerotic lesion development, causing thinning of the extracellular matrix cap, which makes plaques prone to rupture \(^{(10)}\). Levels of IL-6 were also shown to be associated with the angiotensin II expression and may contribute to the inflammatory processes within the vascular wall and development of cardiovascular complications \(^{(17)}\).

In our study, the level of IL-6 was significantly correlated with \(^{18}\)F-FDG-PET uptake in carotid and femoral atherosclerotic lesions, which indicates that increased circulating levels of IL-6 are most probably the consequence of inflamed atherosclerotic plaques in the investigated arterial segments. Particularly, carotid stenotic atherosclerotic lesions usually express a more intensive inflammatory process than occlusive lesions of femoral arteries \(^{(10)}\). Atherosclerotic plaques, particularly, unstable ones, are metabolically more active than thrombotic material, which is a cause of occlusion of femoral artery. Therefore, the finding that patients with ICA stenosis have higher levels of IL-6 (indicator of vessel wall inflammation) than patients with thrombotic occlusion of CFA supports the hypothesis that the inflammation is probably more intensive in non-occlusive carotid lesions.

The involvement of IL-6 in atherogenesis is also supported by findings that IL-6 modulates lipid homeostasis, vascular remodeling, and plaque inflammation in atherogenesis \(^{(18)}\). Further, high levels of IL-6 have been shown to be associated with lower echogenicity of carotid plaques, suggesting a link between inflammation and the potential risk of plaque ruptures \(^{(19)}\). However, IL-6 level elevation is nonspecific and is also secreted by T cells during infection \(^{(20)}\).

In our study, the level of hsCRP was also significantly correlated with \(^{18}\)F-FDG-PET values, which again indicates that inflamed atherosclerotic plaques may cause a systemic inflammatory response. hsCRP is a well-known circulating marker of atherosclerosis, and its levels correlate with the presence of cardiovascular disease. hsCRP is most probably directly involved in atherogenesis; it binds to a modified form of low-density lipoprotein (LDL), and when aggregated, hsCRP can also bind to native LDL \(^{(21)}\).

Therefore, different mechanisms have been identified by which hsCRP modulates and evolves the process of atherosclerosis. However, hsCRP is a much less specific indicator of vessel wall inflammation than ILs. In our study, circulating levels of IL-6 and hsCRP were both increased and correlated with the intensity of inflammation of atherosclerotic plaques shown by \(^{18}\)F-FDG-PET uptake. Similar findings were reported by the Yamagami group, who discovered that increased levels of IL-6 and hsCRP appear to be associated with lower echogenicity of carotid plaques, which indicates inflammation of atherosclerotic lesions \(^{(22)}\).

TNF-\(\alpha\), a pleotropic cytokine exerting both inflammatory and cell death modulatory activity, is also one of the inflammatory markers. It is thought to play a role in the pathogenesis of atherosclerosis, particularly myocardial ischemia, reperfusion injury, and heart failure \(^{(23)}\). Plasma concentration of TNF-\(\alpha\) is also

### Table 5. Systemic inflammatory markers in ICA and CFA groups, respectively before (B) and after (A) endarterectomy.

| Parameter     | ICA-B (n=21) | ICA-A (n=15) | CFA-B (n=16) | CFA-A (n=12) | (ICA + CFA) B vs (ICA + CFA) A |
|---------------|--------------|--------------|--------------|--------------|---------------------------------|
| hsCRP (mg/L)  | 2.5 ± 1.5    | 2.4 ± 1.1    | 2.7 ± 1.7    | 2.4 ± 1.3    | 0.43                            |
| IL-6 (ng/L)   | 3.2 ± 2.5    | 1.8 ± 1.0    | 1.8 ± 1.3    | 1.7 ± 1.4    | 0.06                            |
| TNF-\(\alpha\) (ng/L) | 2.1 ± 0.6 | 1.9 ± 0.8    | 2.3 ± 0.7    | 2.2 ± 0.9    | 0.27                            |
| P-selectin (µg/L) | 48.5 ± 20.3 | 42.7 ± 19.4 | 36.7 ± 17.4 | 38.1 ± 16.5 | 0.41                            |

Abbreviations: ICA – internal carotid artery stenosis, CFA – common femoral artery occlusion, hsCRP – high sensitivity C-reactive protein, IL-6 – interleukin 6, TNF-\(\alpha\) – tumour necrosis factor alpha
persistently elevated among postmyocardial infarction patients and is related to increased risk of cardiovascular events. It again indicates that a persistent inflammatory process is associated with increased vascular risk\(^2\). TNF-\(\alpha\) alters endothelial and vascular smooth muscle cell function as well as endothelial and blood cell interaction. It also promotes the expression of adhesion molecules on endothelial cells and initiation of an inflammatory cascade inside the arterial wall\(^2\). TNF-\(\alpha\) may also interfere with triglycerides and cholesterol metabolic pathways. It promotes hepatic cholesterol synthesis and decreases high-density lipoprotein cholesterol\(^2\). In our study, TNF-\(\alpha\) was significantly related to the intensity of inflammation of the atherosclerotic plaques, indicated by increased uptake of 18F-FDG-PET. This finding confirms that patients with inflamed atherosclerotic plaques have increased levels of inflammatory markers, which are most probably a consequence of increased synthesis and release of these markers by the inflamed atherosclerotic lesions. Nevertheless, most of these patients were treated with statins, which inhibit inflammatory response and stabilize atherosclerotic plaques. In our study, inflammation was most probably not completely inhibited and consequently circulating levels of biomarkers of inflammation remained elevated. Measurement of circulating markers after 1–2 years after the endarterectomy showed that the levels of most of the inflammatory markers were not significantly different compared with the preoperative period. It indicates that atherosclerosis is a systemic disease where patients with atherosclerotic plaques or occlusions in one region most probably also have atherosclerotic lesions in other parts of the arterial system. Elimination of a single atherosclerotic lesion with endarterectomy does not cure the disease; therefore, patients are at a high risk of cardiovascular events in other parts of the circulatory system. Borderline decrease of IL-6 levels after operative procedure indicates that this inflammatory marker is an indicator of vessel wall alteration and inflammation. Therefore, in addition to local surgical intervention, these patients need intensive antiatherosclerotic treatment and prevention including antiplatelet and lipid-lowering drugs, which stabilize atherosclerotic lesions and decrease inflammation in atherosclerotic plaques. Tahara et al. showed that 18F-FDG-PET signals in atherosclerotic lesions were suppressed after a 3-months treatment with a statin\(^2\). In our study, most of the patients were treated with statins; however, less than half of them had reached target levels of cholesterol. Therefore, in our study, it was not possible to exactly estimate the influence of the statins on the 18F-FDG uptake and levels of circulating inflammatory markers.

**Methodological Consideration**

Circulating inflammatory markers are nonspecific, and an increase in their levels can be caused by different diseases, particularly, systemic inflammatory diseases and traumatic tissue damage. Therefore, the results should be interpreted with caution as there is still no definitive answer to whether increased levels of these markers are the cause or the consequence of arterial wall inflammation in atherosclerosis. After the exclusion of other causes, a moderate or mild increase of some markers, particularly ILs, may indicate vessel wall inflammation.

In our study, inflammation of atherosclerotic plaques was investigated through 18F-FDG uptake combined with contrast-enhanced CT. For the quantification of 18F-FDG uptake in an atherosclerotic plaque, measurement of the standardized uptake value of the artery of interest was used, and background 18F-FDG uptake of the blood was measured to calculate maximal TBR\(^9\). There are several methodological considerations regarding the methodology of arterial imaging using 18F-FDG-PET. Recent evidence indicates that maximal TBR is probably the most reproducible value for the measurement of 18F-FDG uptake in the carotid arteries\(^1\). However, because FDG is taken up by any metabolically active tissue, concerns have been raised about the specificity of this tracer for imaging inflammatory cells. Further, blood glucose level can influence FDG uptake, particularly in diabetic patients\(^2\). On the other hand, studies have shown that FDG uptake is significantly correlated with the components of metabolic syndrome\(^2\). Various drugs can also influence FDG uptake, particularly anti-inflammatory drugs and statins. In our study, all these factors that can potentially influence FDG uptake with the exception of statins were excluded.

**Conclusion**

The evidence supports the central role of inflammation in atherogenesis. Consequently, it is expected that patients with inflamed atherosclerotic plaques have increased levels of circulating markers, particularly hsCRP and ILs. Our study confirmed that the levels of some circulating markers (IL-6, TNF-\(\alpha\), and hsCRP) that indicate inflammation of the vessel wall were correlated with the intensity of the inflammatory processes in atherosclerotic plaques, as shown by 18F-FDG-PET. In spite of the fact that these markers are nonspecific indicators of vessel wall inflammation,
after exclusion of other inflammatory processes, determination of circulating markers has the potential to identify individuals with unstable, inflamed atherosclerotic plaques who are at the highest risk for future cardiovascular events and may benefit from more aggressive preventive interventions.

**Funding**

This study was realized with the support of the research program P3-0308 financed by the Slovenian Research Agency.

**Conflict of Interest**

None.

**References**

1) Poredoš P. Peripheral arterial occlusive disease increases the risk of perioperative complications. Vasa. 2014; 43: 401-403

2) Naghavi M, Libby P, Falk E, Cassells SW, Litovsky S, Rumberger J. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003; 108: 1664-1672

3) Schwarz SM, Galis ZS, Rosenfeld ME, Falk E. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol. 2007; 27: 705-713

4) Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50: 892-896

5) Hubalewska-Dydejczyk A, Stompór T, Kalembkiewicz M, Krzanowski M, Mikolajczak R, Sowa-Staszczak A. Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study. Perit Dial Int. 2009; 29: 568-574

6) Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke. 2005; 36: 2764-2772

7) Blockmans D, Maes A, Stroobants S, Nuyts J, Bormans G, Knockaert M. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomo- graphy. Rheumatology (Oxford). 1999; 38: 444-447

8) Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen C, Tong C. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008; 49: 871-878

9) Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708-2711

10) Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res. 2009; 50: S364-369

11) Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-874

12) Sillesen H. What does ‘best medical therapy’ really mean? Eur J Vasc Endovasc Surg. 2008; 35: 139-144

13) Schieffer B, Schieffer E, Hilfliker-Kleiner D, Hilfliker A, Kovanen PT, Kaartinen M. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372-1378

14) Schieffer B, Selle T, Hilfliker A, Hilfliker-Kleiner D, Grote K, Tietge UJ. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004; 110: 3493-3500

15) Amagasaki H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, Kuwabara K, et al. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques, echolucency on Bmode imaging, and elevated plasma lipid levels. J Vasc Surg. 2002; 35: 137-145

16) Reikerås O, Borgen P. Activation of markers of inflammation, coagulation and fibrinolysis in musculoskeletal trauma. PLoS One. 2014; 9: e107881

17) Reikerås O, Borgen P. Activation of markers of inflammation, coagulation and fibrinolysis in musculoskeletal trauma. PLoS One. 2014; 9: e107881

18) Singh SK, Suress MV, Voleti B, Agrawal A. The connection between Creative protein and atherosclerosis. Ann Med. 2008; 40: 110-120

19) Yamauchi K, Kitagawa K, Nogami T, Hougaku H, Sakaguchi M, Kuwabara K, et al. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke. 2004; 35: 677-681

20) Kleinbongard P, Heusch G, Schulz R. TNApffa in ath- erosclerosis, myocardial ischaemia/reperfusion and heart failure. Pharmacol Ther. 2010; 127: 295-314

21) Rivkind PM, Riffait N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372-1378

22) Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-874

23) Sillesen H. What does ‘best medical therapy’ really mean? Eur J Vasc Endovasc Surg. 2008; 35: 139-144

24) Schieffer B, Schieffer E, Hilfliker-Kleiner D, Hilfliker A, Kovanen PT, Kaartinen M. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372-1378

25) Schieffer B, Selle T, Hilfliker A, Hilfliker-Kleiner D, Grote K, Tietge UJ. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004; 110: 3493-3500

26) Popa C, Netea MG, van Riel PL, van der Meer JW, Stal- enhoef AF. The role of TNF-alpha in chronic inflamma- tion between Creactive protein and atherosclerosis. Ann Med. 2008; 40: 110-120

27) Mehta NN, Torigian DA, Geland JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012(63): e3777
ates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831
28) Silvola JM, Saraste A, Laitinen I, Savisto N, Laine VJ, Heinonen SE. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging. 2011; 4: 1294-1301
29) Narumi H, Yoshida K, Funabashi N, Hashimoto N, Umehara I, Yoshida S. Abstract 5825: Association between Patterns of FDG Uptake and Arterial Wall Calcification on PET/CT and Atherogenic Risk Factors in Healthy Subjects. Circulation, 2008: S1012